<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04329806</url>
  </required_header>
  <id_info>
    <org_study_id>190479</org_study_id>
    <nct_id>NCT04329806</nct_id>
  </id_info>
  <brief_title>Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity</brief_title>
  <official_title>Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italo Biaggioni</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the role of sympathetic mechanisms involved in chronic
      regulation of cardiovascular and metabolic abnormalities seen in obesity. We will study the
      effects chronic sympathetic inhibition on insulin sensitivity, inflammation and endothelial
      function in obese hypertensive human subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>6 hours</time_frame>
    <description>Dose response curve to insulin ( measure as glucose infusion rate In mg/kg/min)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obesity-Associated Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Moxonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxonidine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valsartan to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxonidine</intervention_name>
    <description>We will measure insulin sensitivity at baseline and after 9 weeks of treatment</description>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_label>Moxonidine</arm_group_label>
    <arm_group_label>Valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females of all races between 18 and 60 years of age

          -  Hypertension defined by two or more properly measured seated blood pressure readings
             &gt;130/85 mmHg or currently on antihypertensive medication.

          -  Obesity will be defined as having a body mass index (BMI) â‰¥ 30 kg/m2.

          -  Able and willing to provide informed consent.

        Exclusion Criteria:

          -  Pregnancy or breast feeding

          -  Current smokers or history of heavy smoking (&gt;2 packs/day)

          -  History of alcohol or drug abuse

          -  Previous allergic reaction to study medications

          -  Evidence of type I diabetes

          -  Cardiovascular disease other than hypertension

          -  History of serious cerebrovascular disease

          -  History or presence of immunological or hematological disorders

          -  Impaired renal function

          -  Treatment with any investigational drug in the 1 month preceding the study

          -  Inability to give, or withdraw, informed consent

          -  Other factors which in the investigator's opinion would prevent the subject from
             completing the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Italo Biaggioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Italo Biaggioni, MD</last_name>
    <phone>615-875-1516</phone>
    <email>autonomics@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Italo Biaggioni</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxonidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

